Basic Information
LncRNA/CircRNA Name | GAS5 |
Synonyms | NA |
Region | GRCh38_1:173863900-173868882 |
Ensemble | ENSG00000234741 |
Refseq | NR_002578 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 |
Methods | qRT-PCR, Western blotting etc. |
Sample | Two milliliters of whole blood samples |
Expression Pattern | down-regulated |
Function Description | Exo-GAS5 was downregulated in patients with NSCLC compared with healthy controls ( p < 0.001). Furthermore, patients with NSCLC with larger tumor size ( p = 0.025) and advanced TNM (T: extent of the primary tumor; N: lymph node involvement; M: metastatic disease) classification ( p = 0.047) showed lower Exo-GAS5 expression. ROC curve analysis using Exo-GAS5 combined with carcinoembryonic antigen showed an area under curve (AUC) of 0.929. Exo-GAS5 could be used to distinguish patients with Stage I NSCLC with an AUC of 0.822. |
Pubmed ID | 31032916 |
Year | 2019 |
Title | Tumor-derived Exosomal lncRNA GAS5 as a Biomarker for Early-Stage Non-Small-Cell Lung Cancer Diagnosis |
External Links
Links for GAS5 | GenBank HGNC NONCODE |
Links for non small cell lung cancer | OMIM COSMIC |